Viking Therapeutics Completes Patient Enrollment In Exploratory Maintenance Dosing Study Of VK2735, Dual Agonist Of GLP-1 And GIP Receptors

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens

Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735

SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity. 

The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial designed to evaluate various dosing regimens, following initial weight loss achieved with weekly VK2735 treatment. The trial enrolled approximately 180 adults with BMI ≥30 kg/m2 but who are otherwise healthy. 

All enrolled participants receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks.  Following Week 19, participants are transitioned to a range of VK2735 maintenance dosing regimens including weekly, every other week, or monthly subcutaneous dosing, as well as daily oral dosing, weekly oral dosing, or placebo.  The objectives of the study are to evaluate the safety, tolerability, and pharmacokinetic profile of VK2735 under these various dosing regimens.  Exploratory endpoints are assessing change in body weight from baseline, as well as change in body weight from Week 19 to the end of the study at Week 31.